5,388 reports of this reaction
6.5% of all OFATUMUMAB reports
#1 most reported adverse reaction
FATIGUE is the #1 most commonly reported adverse reaction for OFATUMUMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 5,388 FDA adverse event reports linking OFATUMUMAB to FATIGUE. This represents approximately 6.5% of all 82,579 adverse event reports for this drug.
OFATUMUMAB has an overall safety score of 78 out of 100. Patients taking OFATUMUMAB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among OFATUMUMAB users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for OFATUMUMAB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 5,388 FDA reports for OFATUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 6.5% of all adverse event reports for OFATUMUMAB, making it one of the most commonly reported side effect.
If you experience fatigue while taking OFATUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.